News
GSK
49.67
-1.64%
-0.83
AnaptysBio price target raised to $90 from $85 at Leerink
TipRanks · 9h ago
GSK’s B-Well 2 Hepatitis B Trial Reaches Completion, Setting the Stage for Key Data
TipRanks · 10h ago
Biopharmas look to China, elsewhere for partnerships, R&D
Seeking Alpha · 1d ago
Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.
Barchart · 1d ago
UK Stocks-Factors to watch on May 14
Reuters · 1d ago
Trump Trade: Nvidia CEO joins China trip, Diamantas tapped as acting FDA chief
TipRanks · 2d ago
Global Stocks, American Dollars: How ADRhedged™ ETFs Are Fixing the Most Overlooked Risk in International Investing
TipRanks · 2d ago
FDA Commissioner Marty Makary resigns
TipRanks · 3d ago
Trump confirms Kyle Diamantas to be acting head of FDA
TipRanks · 3d ago
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
TipRanks · 3d ago
ARTIOS PHARMA: CLINICAL TRIAL COLLABORATION & SUPPLY AGREEMENT WITH GSK TO EVALUATE ALNODESERTIB IN COMBINATION WITH RISVUTATUG REZETECAN
Reuters · 3d ago
Kennedy driving vast vaccine inquiry despite toned-down criticism, NYT says
TipRanks · 4d ago
GSK enters into exclusive strategic collaboration with Sino Biopharm
TipRanks · 4d ago
Weekly Report: what happened at GSK last week (0504-0508)?
Weekly Report · 4d ago
GSK partners with Sino Biopharmaceutical unit to launch hepatitis B drug in China
PUBT · 4d ago
GSK PLC - GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME
Reuters · 4d ago
Neurizon appoints Ross Murdoch independent non-executive director
PUBT · 5d ago
Trump says unaware of a plan to fire FDA commissioner
Seeking Alpha · 6d ago
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Seeking Alpha · 05/08 17:25
Halozyme announces global collaboration and license agreement with GSK
TipRanks · 05/07 19:48
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).